New Biomarkers to Define A Biological Borderline Situation for Pancreatic Adenocarcinoma - Results of An Ancillary Study of the PANACHE01-PRODIGE48 Trial.
Fiche publication
Date publication
août 2024
Journal
Annals of surgery
Auteurs
Membres identifiés du Cancéropôle Est :
Dr VERNEREY Dewi, Mme HENRIQUES Julie
Tous les auteurs :
Pinson J, Henriques J, Beaussire L, Sarafan-Vasseur N, Sa Cunha A, Bachet JB, Vernerey D, Di Fiore F, Schwarz L,
Lien Pubmed
Résumé
To investigate in patients treated for a resectable pancreatic ductal adenocarcinoma (PA), the prognostic value of baseline CA19-9 and circulating tumour DNA (ctDNA) for overall survival (OS), to improve death risk stratification, based on a planned ancillary study from PANACHE01-PRODIGE 48 trial.
Référence
Ann Surg. 2024 08 5;: